EP0300726B1 - Dérivés pipérazinylés de purines et leur isostères entant qu'agents hypoglycémiques - Google Patents

Dérivés pipérazinylés de purines et leur isostères entant qu'agents hypoglycémiques Download PDF

Info

Publication number
EP0300726B1
EP0300726B1 EP88306584A EP88306584A EP0300726B1 EP 0300726 B1 EP0300726 B1 EP 0300726B1 EP 88306584 A EP88306584 A EP 88306584A EP 88306584 A EP88306584 A EP 88306584A EP 0300726 B1 EP0300726 B1 EP 0300726B1
Authority
EP
European Patent Office
Prior art keywords
mmol
compound
piperazinyl
boc
evaporated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP88306584A
Other languages
German (de)
English (en)
Other versions
EP0300726A1 (fr
Inventor
David B. R. Johnston
Richard L. Tolman
Malcolm Mac Coss
Stephen Marburg
Laura C. Meurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to AT88306584T priority Critical patent/ATE94877T1/de
Publication of EP0300726A1 publication Critical patent/EP0300726A1/fr
Application granted granted Critical
Publication of EP0300726B1 publication Critical patent/EP0300726B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Definitions

  • the instant invention is concerned with novel 6-piperazinopurines and heteroaromatic derivatives thereof, which are useful as hypoglycemic and/or weight reducing agents.
  • novel 6-piperazinopurines and heteroaromatic derivatives thereof which are useful as hypoglycemic and/or weight reducing agents.
  • a still further object is to describe compositions containing such compounds as the active ingredient thereof. Further objects will become apparent from a reading of the following description.
  • the 6-piperazinopurines of this invention are novel compounds with significant hypoglycemic activity.
  • the compounds have the following structures: wherein X and Y have the following meanings: and R 1 and R 3 are independently hydrogen, loweralkyl, cycloloweralkyl, loweralkenyl, loweralkoxyloweralkyl, loweralkenyl, loweralkynyl, phenylloweralkyl or substituted loweralkyl where the substituent is from 1 to 3 of halogen, loweralkylthio, loweralkylsulfinyl, loweralkylsulfonyl, loweralkylamino or diloweralkylamino, or the substituent is one of a 5- or 6-membered heteroaromatic ring system with nitrogen, oxygen or sulfur as the heteroatom, in particular where the hetero aromatic ring system is pyridyl, furyl or thienyl, and m and n are 0 or 1 such that when m is 0, n is 1
  • R 2 and R 4 are independently hydrogen, loweralkyl, cycloloweralkyl, loweralkoxy, loweralkylthio, loweralkylsulfinyl, loweralkylsulfonyl, loweralkenyl, loweralkenyloxy, loweralkynyl, mono, di, or trihaloloweralkyl, phenyl or substituted phenyl where the substituent is from 1 to 3 of halo or loweralkyl, phenylloweralkyl, amino, loweralkylamino or dialkylamino where the alkyl group can be linear, branched or joined in a ring of 5- or 6-members optionally containing oxygen or nitrogen as a heteroatom and the pharmaceutically acceptable salts thereof.
  • the loweralkyl groups of this invention may contain from 1 to 6 carbon atoms and may be in either a linear or branched configuration. Exemplary of such groups are methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, pentyl, hexyl, and the like.
  • the loweralkoxy groups of this invention may contain from 1 to 6 carbon atoms and may be in either a straight or branched configuration. Exemplary of such groups are methoxy, ethoxy, propoxy, butoxy, isobutoxy, pentoxy, hexoxy.
  • the loweralkenyl and loweralkynyl groups of this invention may contain from 2 to 6 carbon atoms and may be in either a linear or branched configuration. Exemplary of such groups are ethenyl, vinyl, butenyl, butynyl, propenyl, propargyl.
  • cycloloweralkyl groups of this invention may contain from 3 to 6 carbon atoms and are exemplified by cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • halogen atoms of this invention may contain any of the halogen fluorine, chlorine, bromine or iodine.
  • amino and substituted amino groups are exemplified by amino, methylamino, dimethylamino, ethylamino, diethylamino, pyrrolidino, morpholino, propylamino, and the like.
  • Preferred compounds of this invention are those wherein R 1 is hydrogen, loweralkyl or loweralkenyl; R 2 is loweralkyl, loweralkoxy, amino, loweralkylamino, diloweralkylamino or pyrrolidino; each R 3 is independently hydrogen, loweralkyl, loweralkoxyloweralkyl or halogenated loweralkyl.
  • R 1 is hydrogen, methyl, ethyl or 2-propenyl
  • R 2 is methyl, ethyl, methoxy, ethoxy, amino, methylamino, dimethylamino, pyrrolidino or ethylamino
  • each R 3 is independently hydrogen, methyl, ethyl, n-propyl, i-propyl, methoxymethyl, methoxyethyl, or fluoroethyl, in particular, a halogenated branched loweralkyl group, in particular a halogenated isopropyl, more prefered as a fluorinated isopropyl, and most preferred as 1,3-difluoro isopropyl; and each R 4 is independently hydrogen, methyl, methylamino or dimethylamino.
  • R 1 is hydrogen.
  • R 2 is methyl, methoxy or ethoxy, R 3 is as defined above, R 4 is hydrogen, X is N and Y is N-R 3 .
  • the pharmaceutically acceptable acid addition salts of the compounds of this invention are included within the ambit of this invention.
  • examples of such pharmaceutically acceptable acid addition salts are those formed from inorganic acids such as hydrochloric, hydrobromic, nitric, sulfuric, phosphoric, dialkylphosphoric, or hypophosphorous; and organic acids such as acetic, benzenesulfonic, benzoic, citric, fumaric, gluconic, lactic, malic, maleic, oxalic, pamoic, pantothenic, salicylic, stearic, succinic, tannic, tartaric, and the like.
  • the instant compounds may also be used in combination with other compounds, in particular combinations with other acid hypoglyceric agents is useful.
  • the instant compounds may be used in combination with sulfonylower for beneficial effect.
  • the foregoing reaction is carried out by reacting an R 1 -substituted piperazine with the chloroheterocy- cle (II).
  • R 1 is hydrogen the reactant can be protected piperazine such that only one of the piperazine nitrogen atoms are available for reaction.
  • the preferred protecting group is the t-butoxycarbonyl (BOC) group. After the protected piperazine has been reacted with the chloroheterocyclic substrate, the protecting group is removed.
  • the displacement of the chloro by the R 1- piperazine or protected piperazine is carried out in an optional solvent at a temperature of from 100 to 150 ° C such that the solvent does not boil at a temperature less than the desired reaction temperature.
  • the preferred solvents are N,N'-dimethylformamide, ethanol, isoamyl alcohol and the like. It is preferred to carry out the reaction at from about 75 to 125°C and the reaction is generally complete in from about 30 minutes to 16 hours. The reaction proceeds well in the absence of a solvent.
  • the piperazine reagent is generally used in at least 1 molar excess in order to neutralize the hydrogen chloride liberated during the course of the reaction. Preferably 4 equivalents of the piperazine compound are employed.
  • a tertiary amine such as triethylamine can be used to reduce the amount of piperazine compound employed in the reaction.
  • the products are isolated from the reaction mixture using standard techniques.
  • the reactions used to prepare the instant compounds are generally carried out with the displacement of the halogen by the R 1- piperazine as the last step.
  • the R 1 group can be introduced on the unsubstituted piperazine after the piperazine has been placed on the heterocycle and after the removal of the protecting group.
  • the reactions used to prepare the heterocycle can include the substitution of the piperazine group prior to the final synthetic steps such as the heterocyclic ring closure or the substitution of the R 2 , R 3 and R 4 groups (See Scheme 1A).
  • the presence of more than one reaction site may result in the preparation of a mixture which will be separated in order to obtain the instant compounds.
  • Diabetes is a condition characterized by abnormal insulin secretion and a variety of metabolic and vascular manifestations reflected in a tendency toward inappropriately elevated blood glucose levels and which if left poorly treated or untreated can result in accelerated, nonspecific atherosclerosis, neuropathy and thickened capillary lamina causing renal and retinal impairment. Diabetes is characterized as being insulin dependent (Type I) and non-insulin dependent (Type II). Type I diabetes is due to damage and eventual loss of the ,8-cells of the pancreatic islets of Langerhans with a resulting loss of insulin production. Type II diabetics secrete insulin, however, the insulin is somehow not properly or effectively utilized in the metabolism of blood sugars and glucose accumulates in the blood to above normal levels. This condition is termed insulin resistance.
  • the compounds of this invention are all readily adapted to their therapeutic use as oral hypoglycemic agents, in view of their ability to lower the blood sugar levels of diabetic subjects to a statistically significant degree.
  • 6-(1-piperazinyl)-9-methylpurine a typical and preferred agent of the present invention, has been found to consistently lower blood sugar levels and improve glucose tolerance in either fasted or fed diabetic (i.e., hyperglycemic) mice to a statistically significant degree when given by the oral route of administration at dose levels ranging from 1 mg/kg to 100 mg/kg, respectively, without showing any toxic side effects.
  • the other compounds of this invention also produce similar results. In general, these compounds are ordinarily administered at dosage levels ranging from about 1 mg to about 100 mg per kg of body weight per day, although variations will necessarily occur depending upon the condition and individual response of the subject being treated and the particular type of oral pharmaceutical formulation chosen.
  • the novel compounds of the invention can be administered in awide variety of different dosage forms, i.e, they may be combined with various pharmaceutically acceptable inert carriers in the forms of tablets, capsules, lozenges, troches, hard candies, powders, aqueous suspension, elixirs, syrups and the like.
  • Such carriers include diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • Such oral pharmaceutical compositions can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for just such a purpose.
  • the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, i.e., in amounts which are sufficient to provide the desired unit dosage.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection would also include the high molecular weight polyethylene glycols.
  • the essential active ingredient therein may becombined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • the activity of the compounds of the present invention is determined by their ability to lower blood sugar levels in the fasted or fed hyperglycemic mouse when tested therein for such purposes according to the procedures described by Saperstein et al. as submitted to the journal Diabetes and summarized as follows: Genetically obese mice (ob/ob) were fasted overnight. The compounds were administered orally via a stomach tube and each mouse serially bled from the orbital sinus at various times and the blood samples were analyzed for blood glucose. When the effects of the compounds on blood glucose levels of fed mice were to be determined, glucose was administered orally at a rate of 2 g per kg. 30 minutes after administration of the test compound. Glucose in the blood was determined by the potassium ferricyanide potassium ferrocyanide oxidation reaction auto analyzer.
  • the latter method measures directly the amount of glucose in the blood at any given time and from this, the maximum percent decrease in blood sugar can be readily calculated and reported as hypoglycemic activity per se.
  • the present compounds are shown to markedly improve glucose tolerance of non-anesthetized hyperglycemic mice when administered to them at dose levels as low as 10 mg/kg orally and lower fasting blood glucose levels when administered at dose levels as low as 30 mg/kg orally.
  • Examples 1-3, 5-7, 9-11, 13, 14, 16-20, 22, 24, 25, 27-31, 33, 34, 37, 38, 40, 41, 44, 45, 47, 48, 50, 51, 53, 55, 57, 59, 61, 62, 64, 66, 68, 70, 74, 75, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95-97, 99, 100, 103, 105, 106, 107, 109-112, 114-119, 121, 122, 124, 127, 128-131 relate to the preparation of intermediates used in the preparation of compounds of the present invention.
  • 6-[1-(4-BOC)piperazinyl]-9-methylpurine (2.5 g, 8.09 mmol) was dissolved in 50 ml of trifluoroacetic acid (TFA) and the solution aged for 1 hour at room temperature. The TFA was removed in a stream of N 2 and the residue dissolved in 2N HCI (20 ml) and the acidic solution evaporated to dryness in vacuo. This HCI treatment was repeated twice and the final residue crystallized from methanolacetonitrile affording 1.71 g (73%) of 6-(1-piperazinyl)-9-methylpurine dihydrochloride, m.p. 300 °C.
  • TFA trifluoroacetic acid
  • 6-Chloropurine riboside (237 mg, 0.834 mmol) and 410 mg (1.86 mmol) of CBZ-piperazine were dissolved in 12 ml of DMF and heated at 100°C for 20 hours. The mixture was then concentrated to dryness in vacuo affording 854 mg of a residue. This was chromatographed on silica gel (60 ml) eluting with equal volumes of methylene chloride, 2% ethanol in methylene chloride (v/v) and finally with 40% ethanol in methylene chloride (v/v) evaporation of appropriate fractions afforded 320 mg (82%) of 6-[1-(4-CBZ)-piperazinyl]purine riboside.
  • a second crop of 0.8 g is obtained by aging at 4 ° C.
  • Example 20 The above 84 mg from Example 20 were dissolved in 4 ml of trifluoroacetic acid (TFA), aged for 1 hr at room temperature and then concentrated to an oily residue by evaporation of the TFA in a stream of N 2 . This residue was dissolved in concentrated HCI (2 ml) and the solution evaporated to dryness. The procedure was repeated twice. The product was slurried in 2.5 ml of ethanol:1 ml acetonitrile for 17 hrs, affording pure 4-(1-piperazinyl)-1-methyl-1H-imidazo(4,5-c)pyridine dihydrochloride.
  • TFA trifluoroacetic acid
  • a glass bomb liner was charged with 0.5 g of 6-[1-(4-BOC)piperazinyl]-8-bromopurine (1.3 mmol), 25 ml MeOH and ca. 10 ml H 2 NCH 3 , sealed, and heated with gentle agitation for 24 hours at 150°C.
  • the dark mixture that resulted was evaporated to a gum with a N 2 -stream and purified by preparative tlc on four 20 x 20 cm x 1000 ⁇ , silica GF plates, developing with 1:10:90-conc.
  • NH 4 OH:MeOH:CHCl 3 to give 204 mg of a brownish gum. This was triturated several times with ether to give 100 mg of a residue which was crystallized from EtOH to give 51 mg (15% yield) of product.
  • 6-Chloro-2,9-dimethylpurine (1.0 g; 5.48 mmol) was dissolved in isopentyl alcohol (90 ml) and 1-BOC-piperazine (1.54 g, 8.25 mmol) was added, followed by triethylamine (1.16 ml; 8.25 mmol). This solution was heated under reflux (bath temp 146 ° C) overnight. The reaction mixture was evaporated to dryness in vacuo, followed by an additional evaporation from toluene. The residue was dissolved in CH 2 CI 2 and the solution was extracted with aqueous 10% Na 2 C0 3 solution. The organic layer was dried over MgS0 4 , filtered, and evaporated to dryness.
  • a glass bomb liner was charged with 0.5 g 6-[1-(4-BOC)piperazinyl]-8-bromo-2,9-dimethylpurine (1.2 mmol), 25 ml MeOH and 10 ml H 2 NCH 3 , sealed, and heated at 130°C for 18 hours with gentle agitation.
  • the recovered solution was concentrated to a gum under a stream of N 2 , and purified on four 20 x 20 cm x 1000 ⁇ silica GF plates, eluting with 0.5:5:95/conc. NH 4 OH:MeOH:CHCl 3 to give 512 mg (1. 4 mmol; 94% crude yield). Recrystallization from EtOH/ether gave 191 mg of product, m.p. 209-211 o.
  • a glass bomb liner was charged with 0.4 g of 6-[1-(4-BOC)piperazinyl]-2,9-dimethyl-8-methylaminopurine (0.97 mmol), 30 ml MeOH, and ca. 10 ml HN(CH 3 ) 2 , sealed and heated with gentle agitation for 15 hours.
  • the recovered material was concentrated to an oil under a stream of N 2 and purified on four 20 x 20 cm x 1000 ⁇ silica GF plates, developed with 1:10:90/conc.NH 4 OH:MeOH:CHCl 3 , to give 331 mg (.98 mmol; quantitative) of crude product. Recrystallization from EtOH gave material with mp 157-159°C.
  • a glass bomb liner was charged with 296 mg of 6-[1-(4-BOC) piperazinyl]-8-bromo-2,9-dimethylpurine (0.72 mmol), 25 ml MeOH, and 10 ml pyrrolidine, sealed, and heated at 130 for 15 hours with gentle agitation.
  • the recovered material was concentrated under a stream of N 2 and purified on four 20x20 cmx1000 ⁇ , silica GF plates developed with 2:120:80/conc.NH 4 OH:MeOH:CHCl 3 to give 0.277 g (0.69 mmol; 95% yield) of crude product. Recrystallization from EtOH gave material with mp. 197-199 °C.
  • Example 32 The procedure used in Example 32 was employed using the corresponding 8-dimethylamino analog (prepared as in Example 31). In this case, the crude product was recrystallized successfully only after excess water was removed by distilling off several portions of absolute EtOH. The final mixture was concentrated and upon standing the product crystallized.
  • Example 32 The process described above in Example 32 was repeated using the 8-(1-pyrrolidinyl) analog (prepared as described in Example 33). As in Example 35, the EtOH azeotropic removal of water was used to encourage crystallization.
  • a glass bomb liner was charged with 0.4 g of 6-[1-(4-BOC)piperazinyl]-8-bromo-9-methylpurine (1.0 mmol), 30 ml MeOH, and ca. 10 ml HN(CH 3 ) 2 , sealed, and heated at 130°C with gentle agitation for 15 hours.
  • the recovered material was concentrated to an oil under a N 2 stream and purified on four 20x20cmx1000 ⁇ , silica GF plates developed with 1:10:90/NH 4 OH:MeOH:CHCl 3 to give 320 mg of a yellowish oil (1.02 mmol; quantitative). It could be crystallized from a highly concentrated solution in MeOH.
  • a glass bomb liner was charged with 0.4 g 6-[1-(4-BOC)piperazinyl]-8-bromo-9-methylpurine (1.01 mmol), 30 ml of MeOH, and 10 ml of pyrrolidine, sealed, and heated at 130 ° C with gentle agitation for 15 hours.
  • the recovered material after concentration to an oil under a N 2 stream, was purified on four 20x20cmx1000 ⁇ , silica GF plates developed with 3.30:70/NH 4 OH:MeOH:CHCl 3 to give 327 mg (0.84 mmol; 83% crude yield) of the title compound. Recrystallization from EtOH gave 146 mg pure product.
  • 6-[1-(4-BOC)piperazinyl]-2-chloro-9-methylpurine 352.8 mg, 1.0 mmol was dissolved in distilled morpholine (5 ml) and heated (bath-temp. 150°C) under N 2 for 27 hours. The reaction mixture was cooled to room temperature and then evaporated to dryness in vacuo (several times from toluene to remove the last traces of morpholine). The residue was dissolved in a minimum amount of CH 2 CI 2 and absorbed onto silica gel 60. This was placed on top of a silica gel 60 column (40 g) packed in hexanes.
  • 6-[1-(4-BOC)piperazinyl]-2-chloro-9-methylpurine (0.396 g; 1.12 mmol) was dissolved in EtOH (15 ml) and pyrrolidine (10 ml) was added. This solution was heated under reflux (bath temp 120-130 °C) for 6 hours and allowed to cool to room temperature. The mixture was evaporated to dryness and the residue was separated between CH 2 CI 2 (70 ml) and 10% aq. Na 2 C0 3 (70 ml). The aq.
  • 6-[1-(4-BOC)piperazinyl]-2-chloro-9-methylpurine (0.352 g; 1.0 mmol) was dissolved in n-butanol (30 ml) and 40% aq. dimethylamine (10 ml) was added. This mixture was heated in a sealed tube at 150°C for 24 hours, at which point tlc indicated no starting material remaining, but two products were apparent. The reaction mixture was blown down under a stream of nitrogen and then was evaporated to dryness. This residue was absorbed onto silica gel 60 from a methanolic solution, and then was fractionated on a silica gel 60 column (30 g).
  • 6-[1-(4-BOC)piperazinyl]-2-dimethylamino-9-methylpurine (0.48 g; 133 mmol) was dissolved in dioxane (25 ml), with warming, and a solution of K 2 HP0 4 2.39 g) in H 2 0 (25 ml) was added. To this well-stirred solution was added bromine (0.2 ml), dropwise over a period of 1-2 min. After 45 min. at room temperature, the reaction was blown under a stream of nitrogen and evaporated to dryness. The residue so obtained was separated between CH 2 CI 2 (60 ml) and 10% aq.
  • Example 70 The foregoing material prepared in Example 70, (0.700 g; 2.77 mmol) was added to anhydrous dimethylamine (5 ml; condensed in a pressure tube) and chilled EtOH (8 ml) was added. The tube was sealed and heated at 110°C for 5 1/2 hours, during which time dissolution occurred. Upon cooling to room temperature a solid formed and the cooled mixture was blown down to dryness under a stream of nitrogen. The residue was dissolved in CH 2 CI 2 and extracted with 10% aq. Na 2 C0 3 and the organic phase was dried (MgS0 4 ), filtered and evaporated to dryness to give 0.650 g (2.49 mmol; 90% yield) of the title compound as the free base.
  • 2-Amino-6-chloropurine (508 mg, 3.00 mmol) was suspended in sieve-dried DMF (20 ml) and piperazine (516 mg; 5.99 mmol) was added. Dissolution occurred and the mixture was heated at 100°C overnight under nitrogen. A precipitate formed which was filtered off and washed with Et 2 0 (yield, 380 mg). A portion (50 mg) was dissolved in 2N HCI (1 ml) and centrifuged, the supernatant was removed and cooled in an ice-bath and the crystalline product (40 mg) was isolated by centrifugation and dried in vacuo at 70 ° C for 12 hours over P 2 0s.
  • Example 50 The material prepared in Example 50 (3.73 g, 11.0 mmol) was dissolved in sieve dried DMF (100 ml) and 60% NaH in oil (660 mg, 16.5 mmol of NaH) was added and the mixture was stirred under nitrogen until the effervescence ceased. 1-lodopropane (1.23 ml, 12.65 mmol) was added and the reaction was stirred at room temperature overnight. The mixture was evaporated to dryness in vacuo and the residue was dissolved in CH 2 CI 2 and this solution was washed with 10% aqu. Na 2 CO 3 , dried over MgS0 4 , filtered and evaporated to a yellow oil.
  • Example 74 The foregoing material prepared in Example 74 (72.52 g, 0.17 mol) was dissolved in methanol (1.06 L) and 122 ml of 4.38 M methanolic sodium methoxide was added. This solution was heated under reflux under N 2 for 48 hrs. and then additional sodium methoxide (12 ml) was added, followed by another 6 ml after a further 24 hrs. After 96 hrs total reaction, the mixture was evaporated to dryness and the residue was partitioned between CH 2 CI 2 (1 L) and H 2 0 (400 ml).
  • Example 75 The foregoing material prepared in Example 75 (51.5 g, 0.137 mol) was dissolved in MeOH (1.5 L) and 1.5L of methanolic HCI was added carefully. This mixture was stirred at room temperature for 1 1/2 hr. and then was concentrated first under a stream of N 2 and then on an evaporator to 600 ml. Precipitation occurred and Et 2 0 (IL) was added. The white solid was filtered off and washed well with Et 2 0. Yield 39.4 g, and a second crop gave 3.54 g. Total yield 0.123 mol, 90%. Mp 205-207 °C
  • Example 74 The material prepared in Example 74 (300 mg, 0.76 mmol) was dissolved in t-butanol (10 ml) and sodium methylthiolate (213 mg, 3.04 mmol) was added. This mixture was refluxed under N 2 for 48 hrs. and then volatiles were removed under a stream of N 2 . The residue was taken up in CH 2 CI 2 (100 ml) and 10% aqueous Na 2 C0 3 (20 ml) and the layers were separated. The aqueous layer was washed two more times with CH 2 CI 2 (2 x 20 ml) and the pooled organic layers were dried (MgS0 4 ), filtered, and evaporated to dryness.
  • Example 77 The foregoing material prepared in Example 77 (150 mg, 0.38 mmol) was dissolved in EtOH (7.5 ml) and ethanolic HCI (3.5 ml) was added. After standing at room temperature for 1 hr, the mixture was concentrated in 1 ml under a stream of N 2 . Precipitation of the product was completed by the addition of Et 2 0 (4 ml) and the title compound was filtered and washed with Et 2 0 (2 x 2 ml). Yield 126 mg (0.34 mmol, 89%).
  • Example 50 The material prepared in Example 50 (1.02 g, 3.0 mmol) was dissolved in sieve dried DMF (25 ml) and 60 °NaH in oil (180 mg, 4.5 mmol of NaH) was added and the mixture was stirred under N 2 . When a homogeneous solution was obtained, bromomethyl methyl ether (0.27 ml, 3.3 mmol) was added and the mixture was left stirring at room temperature under N 2 overnight. Additional bromomethyl methyl ether (0.05 ml) was added followed, at hourly intervals, by two additional 24 mg amounts of 60% NaH in oil. Cold H 2 0 (25 ml) was added slowly, followed by 10% aqueous Na 2 C0 3 (10 ml).
  • Example 80 The foregoing material prepared in Example 80 (255 mg, 0.65 mmol) was dissolved in CF 3 COOH (4 ml) and stirred at room temperature for 40 min. The mixture was concentrated and to the residual oil was added a small amount of Dowex 1x2(0H) resin, followed by 1 drop of conc. NaOH (to ensure basicity). This total mixture was then poured onto a Dowex 1x2(OH) column and developed with H 2 0. Fractions containing the required product were pooled and evaporated to give 70 mg (0.24 mmol) of the title compound as the free base. This was dissolved in EtOH (2 ml) and 56 mg (0.49 mmol) of maleic acid in EtOH (3 ml) was added.
  • Example 50 The material prepared in Example 50 (847 mg, 2.5 mmol) was dissolved in sieve dried DMF (25 ml) and 60% NaH in oil (105 mg, 2.62 mmol of NaH) was added. After 20 minutes stirring under N 2 , evolution of H 2 had ceased and chloromethyl ethyl ether (0.255 ml, 2.75 mmol) was added. After 3 hrs at room temperature, tlc indicated complete reaction and the mixture was concentrated at 65 ° under a stream of N 2 (with NaHCO 3 outlet tube). The mixture was then evaporated to dryness and the residual oil was partitioned between CH 2 CI 2 and 10% aqueous Na 2 CO 3 .
  • Example 82 The foregoing material prepared in Example 82 (300 mg, 0.75 mmol) was added to a solution of methanolic sodium methoxide (0.69 ml of 4.37M solution) in methanol (6 ml) and the mixture was heated under reflux under N 2 for 42 hrs. The solution was then cooled and carefully neutralized with acetic acid before being evaporated to dryness. This residue was partitioned between CH 2 CI 2 and 10% aqueous Na 2 C0 3 and the organic layer was dried (MgS0 4 ), filtered and evaporated to dryness.
  • Example 83 The foregoing material prepared in Example 83 (170 mg, 0.43 mmol) was dissolved in CF 3 COOH (3 ml) and stirred at room temperature for 30 min before being concentrated to dryness. To this residual liquid was added a small amount of Dowex 1x2(OH) resin in H 2 0 and the slurry was placed atop a Dowex 1x2-(OH) column which was then developed with H 2 0. Fractions containing the required product were pooled and evaporated to dryness in vacuo to give 37 mg (0.13 mmol, 29%) of the produt as its free base.
  • Example 50 The material prepared in Example 50 (1.02 g, 3.0 mmol) was dissolved in sieve dried DMF (25 ml) and 180 mg of 60% NaH in oil (4.5 mmol of NaH) was added. This mixture was stirred under N 2 until evolution of H 2 had ceased. Bromomethylcyclopropane (0.35 ml, 3.6 mmol) in DMF (0.5 ml) was added and the reaction was stirred at room temperature under N 2 overnight. The mixture was neutralized with acetic acid and evaporated to a semi-solid residue which was partitioned between EtOAc and 10% aqueous Na 2 CO 3 . The organic layer was dried (MgS0 4 ), filtered and evaporated to dryness.
  • Example 86 The foregoing material prepared in Example 86 (260 mg, 0.65 mmol) was dissolved in abs. EtOH (6 ml) and ethanolic HCI (2 ml) was added. This solution was concentrated slowly under a stream of N 2 . A white precipitate formed which was washed well with Et 2 0. Yield 222 mg (0.59 mmol, 92%). Mass spec (EI) showed M + (free base) at 302 m/e.
  • Example 50 The material prepared in Example 50 (1.02 g, 3.0 mmol) was dissolved in sieve dried DMF (25 ml) and 60% NaH in oil (180 mg, 4.5 mmol of NaH) was added and the mixture was stirred under N 2 . When a homogeneous solution was apparent 2-bromoethyl methyl ether (0.33 ml, 3.6 mmol) was added and the reaction was left stirring overnight. Additional 2-bromoethyl methyl ether (0.085 ml) was then added followed by sodium iodide (90 mg, 0.6 mmol). After stirring for an additional 24 hrs. the mixture was neutralized with acetic acid and evaporated to dryness in vacuo.
  • Example 50 The material prepared in Example 50 (1.02 g, 3.0 mmol) was dissolved in sieve dried DMF (25 ml) under N 2 and 60% NaH in oil (156 mg, 3.9 mmol of NaH) was added. After the evolution of H 2 had ceased, chloromethyl methyl sulfide (0.3 ml, 3.6 mmol) in DMF (3 ml) was added and the reaction was stirred at room temperature for 3 days. Cold H 2 0 (25 ml) was carefully added, followed by 10 ml of 10% aqueous Na 2 COa. After stirring for 1 hr the mixture was evaporated to dryness in vacuo and the residual solid was partitioned between EtOAc and 10% aqueous Na 2 CO 3 .
  • Example 50 The material prepared in Example 50 (2.03 g, 6.0 mmol) was dissolved in sieve dried DMF (50 ml) and 60% NaH in oil (336 mg, 8.4 mmol of NaH) was added. This mixture was stirred under N 2 until hydrogen evolution had ceased and then 2-(trimethylsilyl)ethoxymethyl chloride (1.17 ml, 6.6 mmol) was added. The reaction was stirred under N 2 at room temperature for 24 hrs. and then cold H 2 0 (50 ml) was added, followed by 10% aq. Na 2 C0 3 (20 ml). This mixture was evaporated to dryness and the solid residue was partitioned between CH 2 CI 2 and 10% aq. Na 2 C0 3 .
  • Example 94 The foregoing material prepared in Example 94 (957 mg, 2.04 mmol) was added to a solution of 4.37 M methanolic sodium methoxide (1.87 ml) in MeOH (20 ml) and the mixture was heated under reflux under N2 for 3 days. The mixture was neutralized with acetic acid and then evaporated to dryness to give a solid residue which was partitioned between EtOAc and 10% aqueous Na 2 CO 3 . The organic phase was dried (MgS0 4 ), filtered and evaporated to dryness. This material was purified on a dry-packed silica gel 60 column (70 ml) developed with a step gradient of (1:4 to 2:3) of EtOAc : hexanes. Fractions containing the required product were pooled and evaporated to dryness to give 794 mg (1.71 mmol, 84%) of the title compound as a white solid. Mp 109-110 °C.
  • Example 95 The foregoing material prepared in Example 95 (782 mg, 1.68 mmol) was dissolved in dry THF (9 ml) and 9 ml of a 1 M solution of tetrabutylammonium fluoride in THF was added. This solution was heated at 60 overnight and then an additional 2 ml of 1 M tetrabutylammoniumfluoride in THF was added and the heating was continued at 70 °for an additional 6 hrs. This mixture was evaporated to dryness and the orange residual oil was purified on a dry packed silica gel 60 column (80 ml) developed with a step gradient (1 : 4 to 2 : 3) of acetone : hexanes. Fractions containing the required product were pooled and evaporated to dryness to give 358 mg (1.07 mmol, 64%) of the title compound as a tlc pure white solid.
  • Example 96 The foregoing material prepared in Example 96 (102.8 mg, 0.31 mmol) was dissolved in sieve dried DMF (3 ml) and stirred under N 2 . To this solution was added 60% NaH in oil (16 mg, 0.4 mmol of NaH) and when H 2 evolution had ceased, 1-bromo-2-fluoroethane (50 mg, 0.4 mmol) was added. After stirring overnight the mixture was neutralized with acetic acid and evaporated to dryness. This residue was partitioned between EtOAc and 10% aqueous Na 2 C0 3 and the organic phase was dried (MgS0 4 ), filtered and evaporated to dryness.
  • Example 117 A mixture of the material prepared in Example 117 (50 mg, 0.13 mmol) and methanol (0.5 ml) containing sodium methoxide (0.5 mmol) was refluxed under a nitrogen atmosphere for 18 hours. After cooling, the reaction treated with a mixture of 1 M K 2 P0 4 and CHCl 3 , and after thorough mixing the phases were separated. The aqueous phase was reextracted with CHCl 3 and the organic phases dried (MgS0 4 ) and evaporated to give 60 mg of a crystalline residue.
  • Example 97 The foregoing material prepared in Example 97 (78 mg, 0.26 mmol) was dissolved in abs. EtOH (4 ml) and 2 ml of ethanolic HCI was added. After standing at room temperature for 30 min the solution was slowly concentrated using a stream of N 2 . The white solid so obtained was washed with EtOH and Et 2 0 and dried to give 58.9 mg (0.16 mmol, 62%) of the title compound. The 0.2 molar equivalents of EtOH in the analytical sample were verified by NMR.
  • Example 96 The material prepared in Example 96 (150 mg, 0.45 mmol) was dissolved in sieve dried DMF (3 ml) and 60% NaH in oil (27 mg, 0.67 mmol of NaH) was added. This mixture was stirred under N 2 until hydrogen evolution had ceased and then propargyl bromide (80% by wt in toluene; 0.06 ml, 0.54 mmol) was added. The mixture was stirred at room temperature overnight under N 2 and then was neutralized with acetic acid before being evaporated to dryness. This solid residue was partitioned between CH 2 CI 2 and 10% aq. Na 2 C0 3 and the organic phase was dried (MgS0 4 ), filtered and evaporated to dryness.
  • Example 99 The material prepared in Example 99 (40 mg, 0.11 mmol) was deblocked in the usual way with ethanolic HCI to give 24 mg (0.07 mmol, 617.) of the title compound. Mass spec. (EI) showed M + (free base) at 272 m/e.
  • Example 100 The material prepared in Example 100 (63 mg, 0.17 mmol) was deblocked in the usual way with ethanolic HCI to give 60.2 mg (0.16 mmol, 97%) of the title compound.
  • Mass spec. (EI) showed M+ + H (free base) at 273 m/e.
  • the 0.25 molar equivalents of EtOH in the analytical sample were verified by NMR.
  • Example 96 The material prepared in Example 96 (150 mg, 0.45 mmol) was dissolved in sieve dried DMF (8 ml) and 60% NaH in oil (27 mg, 0.68 mmol of NaH) was added. This mixture was stirred under N 2 until evolution of hydrogen had ceased and then 3-iodopropene (0.05 ml, 0.55 mmol) was added. After stirring for 6 hrs. under N 2 at room temperature, the mixture was evaporated to dryness in vacuo and the residue was partitioned between CH 2 CI 2 (100 ml) and 10% aq. Na 2 C0 2 (20 ml). The organic phase was dried (MgS0 4 ), filtered and evaporated to dryness.
  • Example 103 The foregoing material prepared in Example 103 (133 mg, 0.36 mmol) was deblocked with ethanolic HCI in the usual way to give 101 mg (0.29 mmol, 81 %) of the title compound.
  • Example 107 A portion of the foregoing material prepared in Example 107 was dissolved in ca. 1 ml of CF 3 C0 2 H. After 15-20 minutes, the clear solution was evaporated to a gum under a nitrogen stream, and the residue was partitioned between water and chloroform. The aqueous phase was extracted a second time with chloroform and then made basic by careful addition of solid K 2 C0 3 . The milky aqueous solution was extracted repeatedly with chloroform and the combined organic extracts were dried (MgS0 4 ) and evaporated to dryness to give the title compound, which was crystallized from ether.
  • the aqueous phase was extracted again with CHCl 3 , and the combined organic phases were washed once with water, once with saturated NaCl solution, dried (MgS0 4 ) and evaporated to a gum. This was purified on four 20x20cm x1000 ⁇ silica gel GF plates using EtOAc : hexanes 1 : 4). Isolation and extraction of the main band gave 414 mg of the title compound suitable for further reactions.
  • Example 112 The foregoing material prepared in Example 112 (160 mg) was dissolved in ca. 2 ml of trifluoroacetic acid. After 30 minutes the solution was evaporated to a gum under a nitrogen stream and the residue was partitioned between water and CHCl 3 . The aqueous phase was separated, extracted a second time with CHCl 3 , then made basic by careful addition of solid K 2 C0 3 , and saturated with solid NaCI. The milky solution was extracted several times with CHCl 3 and the combined organic phases were washed once with saturated NaCl solution, dried (MgS0 4 ) and evaporated to give 124 mg of a gum. Recrystallization from hexanes, after removal of a slight flocculant insoluble contaminant, gave 91 mg of the title compound. Mp 104-106°C.
  • Example 50 The material prepared in Example 50 (1.02g, 3.0 mmol) was dissolved in sieved-dried DMF 925 ml) and 60% NaH in oil (156 mg, 3.9 mmol of NaH) was added and the mixture was stirred under N 2 until evolution of H 2 had ceased. Chloroacetone (0.31 ml, 3.9 mmol) was then added and the mixture was stirred under N 2 for 3 days. The reaction was evaporated to dryness and the residue was partitioned between EtOAc and 10% aq. Na 2 CO 3 . The organic phase was dried (MgS0 4 ), filtered and evaporated to dryness to give 1.28 g of a pale yellow oil. Trituration under hexanes gave 1.07g of the title compound, mp 173-175 °C.
  • Example 115 A mixture of the foregoing material prepared in Example 115 (50 mg, 0.12 mmol) and methanol (0.2 ml) containing ca. 0.4 mmol of sodium methoxide was refluxed under a nitrogen atmosphere for 18 hours. After cooling it was treated with a mixture of 1 M KH 2 P0 4 and CHCl 3 and after thorough mixing, the phases were separated. The aqueous phase was extracted again with CHCl 3 and the combined organic extracts dried (MgS0 4 ) and evaporated to give 44 mg of a semicrystalline residue.
  • Example 50 The material prepared in Example 50 (300 mg, 0.89 mmol) was dissolved in sieve dried DMF (5 ml) and 60% NaH in oil (1.5 mmol) of NaH) was added. This mixture was stirred under N 2 until evolution of H 2 had ceased (2 1/2hr). The mixture was centrifuged and the supernatant was added dropwise to a stirred solution of 1-bromo-2-fluoroethane (7.9 mmol) in 1 ml of sieve dried DMF. After stirring overnight at room temperature under N 2 , the residue was partitioned between CH 2 CI 2 and sat. aq. NaHCO 3 . The aqu.
  • Example 118 This was prepared in a manner similar to that described in Example 28 for 6-[1-(4-BOC)piperazinyl]-2,9-dimethylpurine, except that the foregoing material prepared in Example 118 (332 mg, 1.68 mmol) was used as the starting material.
  • the title compound was obtained in good yield after purification on four 20x20cmx1000 ⁇ silica GF plates developed with CHCl 3 : MeOH : NH 4 0H (90 : 10 : 1)
  • Example 119 The foregoing material prepared in Example 119 (300 mg, 0.87 mmol) was deblocked in the usual fashion using ethanolic HCI to give the title compound (197 mg, 0.62 mmol, 71 %) as a white crystalline solid.
  • Example 122 The foregoing material prepared in Example 122 (150 mg, 0.40 mmol) was deblocked in the usual fashion using ethanolic HCI to give the title compound (89.4 mg, 0.26 mmol; 64%) as a white solid. Mass spec. (EI) showed M + (free base) at 276 m/e.
  • Example 96 The material prepared in Example 96 (84 mg, 0.25 mmol) was dissolved in sieve dried DMf (2 ml) and 60% NaH in oil (15 mg, 0.38 mmol of NaH) was added. This mixture was stirred under N 2 under evolution of H 2 had ceased. Chloroacetone (0.03 ml, 0.38 mmol) was then added and the stirring was evaporated to dryness and the residue was partitioned between EtOAc and 10% aq. Na 2 CO 3 . The organic phase was dried (MgS0 4 ), filtered and evaporated to an oil.
  • Example 124 The foregoing material prepared in Example 124 (65 mg, 0.17 mmol) was deblocked using ethanolic HCI in the usual fashion to give the title compound (25.7 mg, 0.07 mmol, 43%) as a white solid. Mass spec. (EI) showed M + (free base) at 290 m/e.
  • Example 116 The material prepared in Example 116 (96 mg, 0.23 mmol) was deblocked in the usual fashion using ethanolic HCI (6.5 ml) to give the title compound (59.8 mg, 0.15 mmol, 65%) as a white crystalline solid.
  • Example 127 The material prepared in the foregoing Example 127 (6.19 g, 32 mmol) was dissolved in 2-propanol (75 ml) and 10 ml of anhydrous ammonia was added. This was sealed in a pressure vessel and heated at 110 for 4 hr. The mixture was vented and then evaporated to a solid residue under a stream of nitrogen.
  • Example 129 The material prepared in the foregoing Example 129 (1.75g, 9.6 mmol), BOC-piperazine (1.97g, 11 mmol), triethylamine (2.8 ml, 20 mmol) and i-amyl alcohol (20 ml) were mixed and heated under reflux under N 2 for 3 hr. The mixture was allowed to cool and the solid was filtered off and washed with a small portion of i-amyl alcohol and then with Et 2 0. Yield 2.1g, 66%.
  • Example 130 The material prepared in the foregoing Example 130 (401 mg, 1.21 mmol) was dissolved in sieve dried DMF (5 ml) and 60% NaH in oil, 73 mg, 1.8 mmol of NaH) was added. This mixture was stirred under N 2 until the hydrogen evolution had ceased. The mixture was centrifuged and the supernatant was added dropwise, with stirring, to a solution of 1-bromo-2-fluoroethane (1.002g, 7.89 mmol) in sieve dried DMF (1 ml). This mixture was stirred under N 2 overnight and then was evaporated to dryness in vacuo.
  • Example 131 The material prepared in the foregoing Example 131 (339 mg, 0.90 mmol) was deblocked in the usual fashion using ethanolic HCI (2.0 ml) to give the title compound (149 mg, 0.4 mmol, 44%) as a white crystalline solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (25)

1. Composé ayant la formule :
Figure imgb0132
où X, et Y ont les significations suivantes :
Figure imgb0133
et R1 et R3 sont, de façon indépendante, un hydrogène, un alkyle inférieur, un cycloalkyle inférieur, un alcényle inférieur, un alcoxy inférieur alkyle inférieur, un alcényle inférieur, un alcynyle inférieur, un phénylalkyle inférieur ou un alkyle inférieur substitué, où
le substituant, en nombre de 1 à 3, est un halogène, un alkylthio inférieur, un alkylsulfinyl inférieur, un alkylsulfonyle inférieur, un alkylamino inférieur, ou un dialkylamino inférieur, ou le substituant est un système cyclique hétéroatomique à 5 ou 6 membres ayant comme hétêroatome l'azote, l'oxygène ou le soufre, et m et n sont 0 ou 1, de telle sorte que lorsque m est 0, n est 1 et lorsque m est 1, n est 0; R2 et R4 sont, de façon indépendante, un hydrogène, un alkyle inférieur, un cycloalkyle inférieur, un alcoxy inférieur, un alkylthio inférieur, un alkylsulfinyle inférieur, un alkylsulfonyle inférieur, un alcényle inférieur, un alcényloxy inférieur, un alcynyle inférieur, un alkyle inférieur mono, di ou trihalogéné, un phényle ou un phényle substitué où le substituant, en nombre de 1 à 3, est un halo ou un alkyle inférieur, un phénylalkyle inférieur, un amino, un alkylamino inférieur ou un dialkylamino où les groupes alkyles peuvent être linéaires, ramifiés ou réunis en cycle ayant 5 ou 6 membres, contenant éventuellement de l'oxygène ou de l'azote comme hétéroatome; où lorsque Ri, R2, R3ou R4est un groupe alkyle inférieur ou alcoxy inférieur, ledit groupe a une configuration linéaire ou ramifié et contient de 1 à 6 atomes de carbone, et lorsque Ri, R2, R3 ou R4 est un groupe alcényle inférieur ou alcynyle inférieur, ledit groupe a une configuration linéaire ou ramifiée et contient de 2 à 6 atomes de carbone, et lorsque Ri , R2, R3 ou R4 est un groupe cycloalkyle inférieur, ledit groupe contient de 3 à 6 atomes de carbone; et leurs sels pharmaceutiquement acceptables.
2. Composé selon la revendication 1, où R1 est un hydrogène, un alkyle inférieur, ou un alcényle inférieur; R2 est un alkyle inférieur, un alcoxy inférieur, un amino, un alkylamino inférieur, un dialkylamino inférieur ou un pyrrolidino; chaque R3 est, de façon indépendante, un hydrogène, un alkyle inférieur, un alcoxy inférieur alkyle inférieur, ou un alkyle inférieur halogéné.
3. Composé selon la revendication 2, où R1 est un hydrogène, un méthyle, un éthyle ou un 2-propényle; R2 est un méthyle, un éthyle, un méthoxy, un éthoxy, un amino, un méthylamino, un diméthylamino, un pyrrolidino ou un éthylamino; chaque R3 est, de façon indépendante, un hydrogène, un méthyle, un éthyle, un n-propyle, un isopropyle, un méthoxyméthyle, un méthoxyéthyle ou un fluoroéthyle; et chaque R4 est, de façon indépendante, un hydrogène, un méthyle, un méthylamino, ou un diméthylamino.
4. Composé selon la revendication 1, ayant la formule
Figure imgb0134
où Y est S ou N-R3 et l'X correspondant est N ou C-R3, et R1, R2, R3 et R4 sont tels que définis dans la revendication 1.
5. Composé selon la revendication 3, où X et Y sont, de façon indépendante, N et N-R3.
6. Composé selon la revendication 5, où X est N et Y est N-R3.
7. Composé selon la revendication 6, où R3 est un alkyle inférieur halogéné ramifié.
8. Composé selon la revendication 7, où R3 est un groupe isopropyle halogéné.
9. Composé selon la revendication 8, où R3 est un groupe isopropyle fluoré.
10. Composé selon la revendication 9, où R3 est le 1,3-difluoroisopropyle.
11. Composé selon la revendication 5, où R1 est un hydrogène ou un méthyle, et R2 et R4 sont, de façon indépendante, un hydrogène, un méthyle, un méthoxy, un éthoxy ou un diméthylamino.
12. Composé selon la revendication 1, qui est X = N, Y = N-CH3, R1 = H, R2 = CH2CH3 et R4 = H.
13. Composé selon la revendication 1, qui est X = N, Y = N-CH2CH2CH3, R1 = H, R2 = OCH3 et R4 = H.
14. Composé selon la revendication 1, qui est X = N, Y = N-CH20CH3, R1 = H, R2 = OCH2CH3 et R4 = H.
15. Composé selon la revendication 1, qui est X = N, Y = N-CH2CH2F, R1 = H, R2 = OCH3 et R4 = H.
16. Composé selon la revendication 1, qui est X = N, Y = N-CH2CH2F, R1 = H, R2 = CH2CH3 et R4 = H.
17. Composé selon la revendication 1, qui est X = N, Y = NCH2CH2CH2F, R1 = H, R2 = OCH3 et R4 = H.
18. Composé selon la revendication 1, qui est X = N, Y = NCH(CH3)2, R1 = H, R2 = OCH3 et R4 = H.
19. Composé selon la revendication 1, qui est X = N, Y = NCH(CH2F)2, R1 = H, R2 = OCH3 et R4 = H.
20. Composé selon la revendication 1, qui est X = NCH-(CH2F)2,R1 = H, R2 = OCH2CH3 et R4 = H.
21. Composé selon la revendication 1, qui est X = N, Y = NCH(CH2F)2, R1 = H, R2 = CH2CH3 et R4 = H.
22. Procédé pour la préparation d'un composé selon la revendication 1, qui comporte le traitement d'un composé ayant la formule :
Figure imgb0135
avec une pipérazine substituée avec Ri , ou une pipérazine protégée où R1 est un hydrogène, où X, Y, Ri , R2 et R3 sont tels que définis ci-dessus.
23. Procédé selon la revendication 22, où la pipérazine est utilisée avec un excès d'au moins une mole.
24. Emploi d'un composé tel que revendiqué dans la revendication 1 pour la préparation d'un médicament utile pour le traitement des diabètes ou de l'obésité associée à une résistance à l'insuline.
25. Composition utile pour le traitement des diabètes ou de l'obésité associée à une résistance à l'insuline qui comporte un support inerte et un composé de formule 1.
EP88306584A 1987-07-20 1988-07-19 Dérivés pipérazinylés de purines et leur isostères entant qu'agents hypoglycémiques Expired - Lifetime EP0300726B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT88306584T ATE94877T1 (de) 1987-07-20 1988-07-19 Piperazinylderivate von purinen und deren isostere als hypoglykaemische wirkstoffe.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7536287A 1987-07-20 1987-07-20
US75362 1987-07-20

Publications (2)

Publication Number Publication Date
EP0300726A1 EP0300726A1 (fr) 1989-01-25
EP0300726B1 true EP0300726B1 (fr) 1993-09-22

Family

ID=22125206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88306584A Expired - Lifetime EP0300726B1 (fr) 1987-07-20 1988-07-19 Dérivés pipérazinylés de purines et leur isostères entant qu'agents hypoglycémiques

Country Status (17)

Country Link
EP (1) EP0300726B1 (fr)
JP (1) JP2562181B2 (fr)
KR (1) KR890002155A (fr)
AT (1) ATE94877T1 (fr)
AU (1) AU601862B2 (fr)
CA (1) CA1341043C (fr)
DE (1) DE3884304T2 (fr)
DK (1) DK403188A (fr)
ES (1) ES2058291T3 (fr)
FI (1) FI883423A (fr)
HU (1) HU199144B (fr)
IL (1) IL87149A (fr)
NO (1) NO167203C (fr)
NZ (1) NZ225447A (fr)
PT (1) PT88029B (fr)
YU (1) YU46761B (fr)
ZA (1) ZA885242B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7737162B2 (en) 2002-07-03 2010-06-15 Gilead Sciences, Inc. Viral inhibitors
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US8017633B2 (en) 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US8329727B2 (en) 2003-12-22 2012-12-11 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
GB8716313D0 (en) * 1987-07-10 1987-08-19 Janssen Pharmaceutica Nv 2-(heterocyclylalkyl)imidazopyridines
GB8922076D0 (en) * 1989-09-28 1989-11-15 Beecham Group Plc Novel process
DK150591D0 (da) * 1991-08-26 1991-08-26 Novo Nordisk As Kemisk forbindelse
US5583137A (en) * 1992-02-19 1996-12-10 Pfizer Inc. Heterocyclic compounds for enhancing antitumor activity
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
WO1999051582A1 (fr) 1998-03-31 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques azotes
AU2003222786A1 (en) * 2002-04-18 2003-10-27 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
EP1568699A4 (fr) * 2002-12-04 2007-08-15 Eisai R&D Man Co Ltd Compose 1,3-dihydro-imidazole a cycle fusionne
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1968948A (zh) 2004-06-17 2007-05-23 惠氏公司 用于制备促性腺激素释放激素受体拮抗剂的方法
CN101006078A (zh) 2004-06-17 2007-07-25 惠氏公司 促性腺素释放激素受体拮抗剂
DE602005013580D1 (de) 2004-12-21 2009-05-07 Leuven K U Res & Dev Imidazoä4,5-cüpyridinverbindung und verfahren zur antiviralen behandlung
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
TWI360549B (en) 2006-07-07 2012-03-21 Gilead Sciences Inc Novel pyridazine compound and use thereof
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2730271A1 (fr) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc Inhibiteurs selectifs des isoformes de la pi3 kinase
CA2730603C (fr) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
EP2405973B1 (fr) * 2009-03-13 2015-04-22 Katholieke Universiteit Leuven, K.U. Leuven R&D Dérivés de thiazolopyrimidine en tant qu'agents immunosuppresseurs
EP2552916B1 (fr) 2010-03-31 2014-05-21 Eli Lilly and Company Composés de purine utilisés comme agonistes de cb2
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (fr) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Procédé de préparation d'agonistes du guanylate cyclase c
WO2014131024A2 (fr) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et applications associées
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
SG11201509014UA (en) * 2013-05-02 2015-11-27 Hoffmann La Roche Purine derivatives as cb2 receptor agonists
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
MX2016001714A (es) 2013-08-09 2016-10-03 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
CN104497085B (zh) * 2015-01-16 2017-05-24 华东理工大学 腺苷衍生物及其用途
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1115260B (de) * 1957-02-27 1961-10-19 Thomae Gmbh Dr K Verfahren zur Herstellung von Purinderivaten
GB1186504A (en) * 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
JPS6210085A (ja) * 1985-07-05 1987-01-19 Yoshitomi Pharmaceut Ind Ltd トリフルオロメチルプリン誘導体

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737162B2 (en) 2002-07-03 2010-06-15 Gilead Sciences, Inc. Viral inhibitors
US8779141B2 (en) 2002-07-03 2014-07-15 Gilead Sciences, Inc. Viral inhibitors
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US8329727B2 (en) 2003-12-22 2012-12-11 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US8017633B2 (en) 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US8541456B2 (en) 2005-03-08 2013-09-24 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus type 2

Also Published As

Publication number Publication date
YU46761B (sh) 1994-05-10
NO167203C (no) 1991-10-16
PT88029B (pt) 1995-03-01
AU601862B2 (en) 1990-09-20
DK403188A (da) 1989-03-30
JPH01104074A (ja) 1989-04-21
ATE94877T1 (de) 1993-10-15
IL87149A (en) 1994-05-30
ZA885242B (en) 1989-03-29
IL87149A0 (en) 1988-12-30
NO883204L (no) 1989-01-23
DK403188D0 (da) 1988-07-19
HUT47575A (en) 1989-03-28
HU199144B (en) 1990-01-29
AU1923088A (en) 1989-01-27
DE3884304T2 (de) 1994-03-24
NZ225447A (en) 1991-12-23
NO883204D0 (no) 1988-07-19
ES2058291T3 (es) 1994-11-01
FI883423A (fi) 1989-01-21
FI883423A0 (fi) 1988-07-19
JP2562181B2 (ja) 1996-12-11
YU141088A (en) 1990-10-31
KR890002155A (ko) 1989-04-08
DE3884304D1 (de) 1993-10-28
CA1341043C (fr) 2000-07-04
EP0300726A1 (fr) 1989-01-25
PT88029A (pt) 1989-06-30
NO167203B (no) 1991-07-08

Similar Documents

Publication Publication Date Title
EP0300726B1 (fr) Dérivés pipérazinylés de purines et leur isostères entant qu'agents hypoglycémiques
US5057517A (en) Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
CA1062257A (fr) Composes de type purine et sels derives
EP2049491B1 (fr) Composés hétéroaryles utiles comme inhibiteurs des enzymes d'activation e1
US4199574A (en) Methods and compositions for treating viral infections and guanine acyclic nucleosides
US9150525B2 (en) Heteroaryl compounds useful as inhibitors of E1 activating enzymes
Mueller et al. Synthesis of paraxanthine analogs (1, 7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors
EP0159264B1 (fr) Composés antiviraux
US7816350B2 (en) Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors
JP4324338B2 (ja) 縮合イミダゾール化合物及び糖尿病治療薬
AU2005298878B2 (en) Purine derivatives for use as adenosin A-2A receptor agonists
TW200831104A (en) 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
KR20150036738A (ko) 신규 헤테로아릴 및 헤테로사이클 화합물, 그의 조성물 및 방법
EP1399446B1 (fr) Derives de purine 2,6,9-substitues et leur utilisation dans le traitement de maladies proliferantes
Shealy et al. Synthesis and antiviral activity of carbocyclic analogs of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines
Perez-Perez et al. Application of the Mitsunobu-type condensation reaction to the synthesis of phosphonate derivatives of cyclohexenyl and cyclohexanyl nucleosides
EP1515972B1 (fr) Derives de xanthine a substitution amide a activite de modulation de la gluconeogenese
Michael et al. Alkylpurines as immunopotentiating agents. Synthesis and antiviral activity of certain alkylguanines
EP0330992A2 (fr) Dérivés de cyclobutane, procédés pour leur préparation et compositions pharmaceutiques les contenant
AU2947789A (en) Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

ITCL It: translation for ep claims filed

Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A.

17P Request for examination filed

Effective date: 19890605

17Q First examination report despatched

Effective date: 19920117

ITTA It: last paid annual fee
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 94877

Country of ref document: AT

Date of ref document: 19931015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3884304

Country of ref document: DE

Date of ref document: 19931028

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3009968

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2058291

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 88306584.9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010530

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20010710

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20010718

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20010725

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010731

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010816

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010827

Year of fee payment: 14

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20020510

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20020523

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20020524

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20020529

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020719

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020719

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020731

BERE Be: lapsed

Owner name: *MERCK & CO. INC.

Effective date: 20020731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030201

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20020719

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20030201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040205

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040331

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050719